Lei Miao

Feb 29, 2024 | cell.com | Christopher Byrne |Lei Miao |Giovanni Targher |IRCCS Sacro Cuore

A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 2020; 73: 202-209The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol. Int. 2020; 14: 889-919Promoting the term MAFLD: China in action. Lancet Gastroenterol. Hepatol.

Feb 29, 2024 | cell.com | Christopher Byrne |Byrne C.D |Lei Miao |Giovanni Targher

HighlightsMetabolic dysfunction-associated steatotic liver disease (MASLD) is now the most widespread global chronic liver disease, affecting over 30% of adults. MASLD has effects beyond adverse liver outcomes, affecting cardiovascular disease, chronic kidney disease, and various extrahepatic cancers. The economic burden of MASLD is substantial, exceeding $100 billion in the USA alone, with liver transplantation being a significant contributor to healthcare costs.